Leukemia Research Foundation of Delaware Invests $1 Million in Pediatric Research Initiative

A Commitment to Pediatric Leukemia Research

The Leukemia Research Foundation of Delaware (LRFDE), initiated by Denni Ferrara, has pledged a significant sum of $1 million to advance pediatric leukemia research through the innovative Dare To Dream Project spearheaded by Blood Cancer United. This initiative promises to transform the landscape of treatment for young patients battling blood cancer.

Denni Ferrara’s dedication to this cause is deeply personal, rooted in both triumph and tragedy. Her journey began when she and her husband, Nick, supported a friend whose son was undergoing treatment for leukemia. Tragically, their lives took a pivotal turn when their own daughter, Natalia, was diagnosed with a high-risk form of leukemia at the tender age of three and a half. This experience ignited Ferrara's passion for advocating better care and funding cutting-edge research in pediatric oncology.

In her own words, Ferrara emphasizes, "Families facing childhood leukemia deserve better options and faster progress." Her statement reflects a profound commitment to ensuring that future generations have access to improved treatments and research methodologies. The recent funding announcement underscores LRFDE's belief in the necessity of urgent and purposeful action in pediatric leukemia research.

The allocated $1 million will specifically support research led by Dr. Alex Stevens. His focus is on enhancing treatment methodologies for children afflicted with acute myeloid leukemia (AML), a rare yet aggressive blood cancer. This funding forms an integral part of The Dare to Dream Project, which is designed to innovate within the PedAL Master Clinical Trial ecosystem.

Dr. Stevens and his research team are currently developing advanced preclinical models — sophisticated laboratory tools that enable scientists to assess potential treatments prior to clinical application. The importance of these models cannot be overstated; they are crucial for representing various subtypes of pediatric AML and allow for informed decisions on the most promising treatment options while expediting their entry into clinical trials.

A significant barrier in cancer research has been the insufficient availability of the right tools for testing potential treatments. By addressing this challenge, the Dare to Dream initiative is paving the way for faster advancements in pediatric cancer care, ensuring that children receive the best possible opportunities for recovery.

This collaborative effort is vital not only in terms of promising new treatments but also in fostering hope among families affected by childhood cancer. Dr. E. Anders Kolb, president and CEO of Blood Cancer United, stated, "The Dare to Dream Project focuses on dismantling obstacles that have historically hindered progress in childhood cancer research." This initiative aims to bring new hope to families, allowing researchers to move forward with pioneering treatments that could alter the trajectory of pediatric cancer care.

In addition to pioneering research, LRFDE continues to engage with the local community to further its mission. An upcoming event, the Endless Summer, is scheduled for June 20, 2026, at the Lighthouse Cove Event Center in Dewey Beach, Delaware. This event is set to raise vital funds to continue advancing blood cancer research and care initiatives.

For anyone interested in contributing to this significant cause or learning more, further information is available on LRFDE’s website. Blood Cancer United, established in 1949, is recognized as the largest global nonprofit organization dedicated to blood cancer patient support, research, and advocacy. Continuously evolving to best serve individuals affected by all forms of blood cancer, the organization champions innovative research, provides invaluable resources, and advocates for improved access to healthcare.

In summary, LRFDE's investment in pioneering pediatric research marks a hopeful dawn for many families struggling with the burdens of childhood leukemia. With strong community backing and innovative strides being made in treatment research, there is a palpable sense of optimism for the future of pediatric cancer care.